世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

呼吸器合胞体ウイルス (RSウイルス) 感染症: パイプラインレビュー 2016年下半期

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016

 

出版社 出版年月電子版価格 ページ数
Global Markets Direct
グローバルマーケッツダイレクト社
2016年11月US$2,000
シングルユーザライセンス
267

サマリー

Global Markets Directによる呼吸器合胞体ウイルス (RSウイルス) 感染症のパイプラインレビューです。



Report Details

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections ? Pipeline Review, H2 2016, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections ? Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 11, 50 and 14 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 4, 13 and 4 molecules, respectively.Respiratory Syncytial Virus (RSV) Infections.

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

目次

Table of Contents
Table of Contents 2
Introduction 6
Respiratory Syncytial Virus (RSV) Infections Overview 7
Therapeutics Development 8
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies 10
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes 14
Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance 15
Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies 18
Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes 23
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 25
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 85
Drug Profiles 95
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 237
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 242
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 243
Appendix 254

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る